Growth hormone peptide stack research in Canada investigates the synergistic GH-releasing properties of GHRH and GHRP combinations. When a GHRH analogue (CJC-1295, sermorelin, tesamorelin) and a GHRP (ipamorelin, GHRP-2, GHRP-6, hexarelin) are administered together, they produce supra-additive GH release that exceeds what either compound produces alone. Canadian pituitary biology and growth hormone axis researchers study this synergy to understand how the two peptide receptor systems interact at the somatotroph level to amplify GH secretion.
Mechanism of GHRH + GHRP Synergy Research
GHRH acts on GHRH receptors (Gs-coupled) to increase cAMP and activate adenylyl cyclase in somatotrophs. GHRPs act on GHS-R1a (Gq-coupled) to increase intracellular calcium via PLC-PKC signalling. The combination of cAMP elevation AND calcium mobilization in the same cell produces synergistic GH vesicle exocytosis through different second messenger pathways converging on the secretory machinery. Canadian researchers study how this dual-pathway activation produces the observed supra-additive GH pulse.
Research Protocol Comparisons
Canadian researchers study multiple GHRH + GHRP combinations: CJC-1295 No DAC + ipamorelin (physiologically pulsatile), CJC-1295 DAC + ipamorelin (sustained baseline), and GHRH + GHRP-2 (maximal stimulation for pituitary reserve testing). Each combination provides different GH pulse dynamics for different research questions about somatotroph secretory biology.
Sourcing GH Peptides in Canada
All GHRH analogues and GHRPs are available from EhBuddy Peptides in Canada. For laboratory research use only.
GHRH + GHRP combination research is among the most active areas of growth hormone axis biology in Canada, providing insights into the dual-receptor mechanism that controls pulsatile somatotroph GH secretion.
